PDGFR-β expression in small cell lung cancer patients

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 17128-17128
Author(s):  
B. Lu
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Prognostic Value ◽  
Treatment Options ◽  
Cell Cancer ◽  
Small Cell ◽  
Tumor Control ◽  
Small Cell Lung ◽  
Significant Difference

17128 Background: Small cell lung cancer (SCLC) carries an extremely poor prognosis and treatment options for this disease remain poor. PDGF and PDGFR-β are expressed and have been found to have prognostic value in several human cancers. Data in non-small cell cancer cell lines have suggested that PDGFR is a therapeutic target for drug development. In the current study PDGFR-β expression and prognostic value in SCLC was investigated. Methods: Paraffin embedded tissue blocks from 53 patients with limited and extensive stage SCLC were obtained for immunohistochemical staining. Tumors from each patient were sampled three times and stained with PDGFR-β specific antibody. Patients were divided into low and high staining groups based on intensity. Results: There was high intensity PDGFR-β staining in 20 patients with SCLC. Another 29 expressed low intensity PDGFR- β staining, with only 4 patients showing no PDGFR- β staining. There was no statistically significant difference in five year overall survival between patients with low levels of PDGFR-β staining versus those with high level staining SCLC tumors (P = 0.538). Conclusions: Though expression of PDGFR-β may not be a predictor of prognosis, due to its high expression in SCLC it may represent an important target for improved tumor control, however, further studies are required to confirm this. No significant financial relationships to disclose.

scholarly journals A Comparison of Survival after Radiosurgery in Non-Small Cell  Lung Cancer  Patients with One versus More than Twenty Brain Metastases

2021 ◽  
Author(s):  
Zhishuo Wei ◽  
Ajay Niranjan ◽  
Hussam Abou-Al-Shaar ◽  
Hansen Deng ◽  
Luigi Albano ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Tumor Development ◽  
Small Cell ◽  
Tumor Control ◽  
Small Cell Lung ◽  
Significant Difference ◽  
Median Margin

Abstract Background Whether the number or cumulative volume of brain metastases affects survival in patients with metastatic non-small cell lung cancer (NSCLC) remains controversial. We sought to compare whether patients with solitary brain disease had better outcomes than patients with ≥ 20 brain metastases. Methods Between 2014 to 2020, 26 NSCLC patients (925 tumors) underwent stereotactic radiosurgery (SRS) for ≥ 20 metastases in a single procedure (median margin dose = 16 Gy, median cumulative tumor volume = 4.52 cc); 56 patients underwent SRS for a single metastasis (median margin dose = 18 Gy, median volume = 4.74 cc). The overall survival (OS), local tumor control (LC), adverse radiation effect (ARE) risk, and incidence of new tumor development were compared. Results No difference in OS was found between patients with ≥ 20 brain metastases (median OS = 15 months) and patients with solitary metastasis (median OS = 12 months; p = 0.3). In the solitary tumor cohort, two of 56 (3.5%) tumors progressed whereas in the ≥ 20 cohort only 3 of 925 (0.3%) tumors showed progression (*p = 0.0013). The rate of new tumor development was significantly higher in patients with ≥ 20 tumors (***p = 0.0001). No significant difference of ARE rate was found (7.5% for ≥ 20 tumors vs. 8.7% for single metastasis). Conclusions Patients with ≥ 20 tumors showed significantly better LC with similar OS compared to patients with solitary tumors. Current guidelines that restrict the role of SRS to patients with 1-4 tumors should be revised.

scholarly journals Correlation between cytological and histopathological diagnosis of non-small cell lung cancer and accuracy of cytology in diagnosis of lung cancer

2020 ◽  
pp. 117-117
Author(s):  
Jelena Dzambas ◽  
Ivan Aleksic ◽  
Vesna Skuletic ◽  
Snezana Cerovic ◽  
Dragana Tegeltija
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Prognostic Value ◽  
Small Cell ◽  
Histopathological Diagnosis ◽  
Cytological Diagnosis ◽  
Small Cell Lung ◽  
Significant Difference ◽  
Sensitivity Specificity

Background/Aim. Lung cancer is one of the most common cancer types worldwide. More than 70% of patients are diagnosed in advanced stages of disease, with limited therapeutic options based on cytological and histopathological material. The value of cytology in diagnosing and subtyping of non-small cell lung cancer is very important for modern personalized therapies. The aim of this study is to find out the concordance between cytological and histopathological diagnosis of non-small cell lung cancer, and the accuracy, sensitivity, specificity, positive and negative predictive value of cytology in diagnosing lung cancer. Methods. Two-year retrospective study included 169 patients with cytological diagnosis of non-small cell lung cancer, histopathological small biopsy and surgical specimens for diagnosis confirmation, that were copmpared. Histopathological diagnosis on surgical specimens was golden standard for evaluation concordance to cytological diagnosis of non-small cell lung cancer and evaluation accuracy, specificity, sensitivity, positive and negative prognostic value of cytology as diagnostic method for detecting lung cancer. Results. This study included 76.3 % (129/169) male and 23.7% (40/169) female, age between 39 and 83, average 62.53?7.6. There was no statistically significant difference between ages of different genders (p=0.207). The most frequent among cytological diagnosis was non-small cell lung cancer in 58.58% (99/169) patients. Concordance between cytological and histopathological diagnoses of surgical specimens was 61.48%. There was no statistically significant difference between cytological diagnoses and histopathological diagnoses of small biopsies specimens (p=0.856). Sensitivity, specificity, positive and negative prognostic value and accuracy of cytology as diagnostic method of lung cancer were 94.98%, 98.60%, 95.72%, 98.35% and 97.71%, respectively. Conclusion. Cytological diagnosis of non-small cell lung cancer is accurate, with high sensitivity, specificity, and benefits for patients. Most patients are diagnosed in advanced stage of cancer when there is no surgical therapy option and the only available diagnostic material is small biopsy sampled during bronchoscopy.

scholarly journals Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record

Cancers ◽  
2020 ◽  
Vol 12 (7) ◽  
pp. 1800 ◽  
Author(s):  
Fabio Pagni ◽  
Umberto Malapelle ◽  
Claudio Doglioni ◽  
Gabriella Fontanini ◽  
Filippo Fraggetta ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Gold Standard ◽  
Digital Pathology ◽  
Small Cell ◽  
Small Cell Lung ◽  
Significant Difference ◽  
Standard Quality ◽  
A Minor

A meeting among expert pathologists was held in 2019 in Rome to verify the results of the previous harmonization efforts on the PD-L1 immunohistochemical testing by scoring a representative series of non-small cell lung cancer (NSCLC) digital slides. The current paper shows the results of this digital experimental meeting and the expertise achieved by the community of Italian pathologists. PD-L1 protein expression was determined using tumor proportion score (TPS), i.e., the percentage of viable tumor cells showing partial or complete membrane staining at any intensity. The gold standard was defined as the final PD-L1 score formulated by a panel of seven lung committed pathologists. PD-L1 status was clustered in three categories, namely negative (TPS < 1), low (TPS 1–49%), and high (TPS ≥ 50%). In 23 cases (71.9%) PD-L1 staining was performed using the companion diagnostic 22C3 pharmDx kit on Dako Autostainer, while in nine (28.1%) cases it was performed using the SP263 Ventana kit on BenchMark platform. A complete PD-L1 scoring agreement between the panel of experts and the participants was reached in 57.1% of cases, whereas a minor disagreement in 16.1% of cases was recorded. Italian pathologists performed best in strong positive cases (i.e., tumor proportion score TPS > 50%), whereas only 10.8% of disagreement with the gold standard was observed, and 55.6% regarded a single challenging case. The worst performance was achieved in the negative cases, with 32.0% disagreement. A significant difference resulted from the analysis of the data separated by the different clones used: 22.3% and 38.1% disagreement (p = 0.01) was found in the group of cases analyzed by 22C3 and SP263 antibody clones, respectively. In conclusion, this workshop record proposed the application of a digital pathology platform to share controversial cases in educational meetings as an alternative possibility for improving the interpretation and reporting of specific histological tools. Due to the crucial role of PD-L1 TPS for the selection of patients for immunotherapy, the identification of unconventional approaches as virtual slides to focus experiences and give more detailed practical verifications of the standard quality reached may be a considerable option.

The prognostic value of residual mediastinal involvement following induction therapy and surgery for locally advanced non-small cell lung cancer

Lung Cancer ◽  
2004 ◽  
Vol 46 (1) ◽  
pp. 125-126
Author(s):  
Stefano Margaritora ◽  
Alfredo Cesario ◽  
Domenico Galetta ◽  
Venanzio Porziella ◽  
Silvia Sterzi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Induction Therapy ◽  
Cell Lung Cancer ◽  
Prognostic Value ◽  
Locally Advanced ◽  
Small Cell ◽  
Small Cell Lung ◽  
Mediastinal Involvement

scholarly journals Comprehensive analysis of prognostic value and immune infiltration of kindlin family members in non-small cell lung cancer

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Xiaoshan Su ◽  
Ning Liu ◽  
Weijing Wu ◽  
Zhixing Zhu ◽  
Yuan Xu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Small Cell Lung Cancer ◽  
Cell Lines ◽  
Cell Lung Cancer ◽  
Prognostic Value ◽  
Small Cell ◽  
Nsclc Cell ◽  
Small Cell Lung ◽  
Immune Infiltration

Abstract Background Kindlin Family Members have been reported to be aberrantly expressed in various human cancer types and involved in tumorigenesis, tumor progression, and chemoresistance. However, their roles in non-small cell lung cancer (NSCLC) remain poorly elucidated. Methods We analyzed the prognostic value and immune infiltration of Kindlins in NSCLC through Oncomine, GEPIA, UALCAN, CCLE, Kaplan‑Meier plotter, cBioPortal, TIMER, GeneMANIA, STRING, and DAVID database. Additionally, the mRNA expression levels of Kindlins were verified in 30 paired NSCLC tissues and NSCLC cell lines by real-time PCR. Results The expression level of FERMT1 was remarkably increased in NSCLC tissues and NSCLC cell lines, while FERMT2 and FERMT3 were reduced. Kindlins expressions were associated with individual cancer stages and nodal metastasis. We also found that higher expression level of FERMT1 was obviously correlated with worse overall survival (OS) in patients with NSCLC, while higher FERMT2 was strongly associated with better overall survival (OS) and first progression (FP). Additionally, the expression of FERMT2 and FERMT3 were obviously correlated with the immune infiltration of diverse immune cells. Functional enrichment analysis has shown that Kindlins may be significantly correlated with intracellular signal transduction, ATP binding and the PI3K-Akt signaling pathway in NSCLC. Conclusions The research provides a new perspective on the distinct roles of Kindlins in NSCLC and likely has important implications for future novel biomarkers and therapeutic targets in NSCLC.

Prognostic value of S-100 immunostaining in tumour cells of non-small cell lung cancer

Biomarkers ◽  
2006 ◽  
Vol 11 (3) ◽  
pp. 262-269 ◽  
Author(s):  
E. Jassem ◽  
K. Serkies ◽  
R. Dziadziuszko ◽  
A. Drozdowska ◽  
G. Kobierska-Gulida ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Prognostic Value ◽  
Small Cell ◽  
Tumour Cells ◽  
Small Cell Lung ◽  
S 100

Current and evolving treatment options for limited stage small cell lung cancer

2006 ◽  
Vol 18 (2) ◽  
pp. 162-172 ◽  
Author(s):  
Carrie B Lee ◽  
David E Morris ◽  
Daniel B Fried ◽  
Mark A Socinski
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Treatment Options ◽  
Small Cell ◽  
Small Cell Lung ◽  
Limited Stage
Sign in / Sign up

Export Citation Format

Share Document